Insider Selling: Exagen (NASDAQ:XGN) Major Shareholder Sells $508,877.40 in Stock

Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 109,436 shares of Exagen stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $4.65, for a total transaction of $508,877.40. Following the completion of the sale, the insider directly owned 2,587,504 shares in the company, valued at $12,031,893.60. This trade represents a 4.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

  • On Friday, November 13th, Jorey Chernett sold 58,068 shares of Exagen stock. The shares were sold at an average price of $4.08, for a total value of $236,917.44.
  • On Wednesday, November 11th, Jorey Chernett acquired 71,315 shares of Exagen stock. The shares were purchased at an average cost of $5.23 per share, with a total value of $372,977.45.
  • On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total value of $69,167.10.
  • On Tuesday, November 10th, Jorey Chernett bought 7,085 shares of Exagen stock. The stock was purchased at an average cost of $5.26 per share, with a total value of $37,267.10.
  • On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The stock was purchased at an average cost of $6.35 per share, with a total value of $53,975.00.
  • On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The stock was purchased at an average price of $7.46 per share, for a total transaction of $104,440.00.

Exagen Stock Performance

Shares of XGN opened at $4.13 on Monday. Exagen Inc. has a 1 year low of $2.59 and a 1 year high of $9.28. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.46 and a quick ratio of 3.46. The stock’s fifty day moving average price is $7.71 and its two-hundred day moving average price is $5.13. The firm has a market cap of $105.37 million, a PE ratio of -5.51 and a beta of 2.25.

Exagen (NASDAQ:XGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. The firm had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.34 million. On average, equities research analysts forecast that Exagen Inc. will post -0.71 EPS for the current year.

Wall Street Analysts Forecast Growth

XGN has been the subject of several recent research reports. Canaccord Genuity Group reduced their target price on shares of Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. Wall Street Zen cut shares of Exagen from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Exagen in a report on Wednesday, November 11th. Finally, TD Cowen raised their price objective on shares of Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.88.

View Our Latest Report on XGN

Trending Headlines about Exagen

Here are a few of the latest headlines about XGN:

  • Positive Sentiment: BTIG reiterated its Buy rating. KeyCorp also forecasts a smaller loss in 2027 than in 2026, although it still expects Exagen to remain unprofitable. Article: Exagen’s Buy Rating Reiterated at BTIG Research
  • Neutral Sentiment: Major shareholder Jorey Chernett recently made purchases as well as sales. KeyCorp’s 2026 loss estimate matches consensus, offering little change to current expectations.
  • Negative Sentiment: Chernett sold 167,504 shares on Nov. 12–13 for about $746,000, a notable signal of insider selling despite his recent purchases. Article: Exagen Major Shareholder Sells Stock

Institutional Investors Weigh In On Exagen

Institutional investors and hedge funds have recently modified their holdings of the company. Flputnam Investment Management Co. grew its holdings in shares of Exagen by 3.8% during the third quarter. Flputnam Investment Management Co. now owns 299,828 shares of the company’s stock worth $2,438,000 after purchasing an additional 11,018 shares in the last quarter. Corient Private Wealth LP bought a new position in shares of Exagen in the second quarter worth approximately $52,000. Penbrook Management LLC bought a new position in shares of Exagen in the third quarter worth approximately $92,000. Calamos Advisors LLC bought a new position in shares of Exagen in the third quarter worth approximately $94,000. Finally, Bank of New York Mellon Corp purchased a new stake in Exagen in the second quarter valued at approximately $97,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Featured Articles

Insider Buying and Selling by Quarter for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.